Key Considerations for Investors as Boundless Bio Makes Nasdaq Debut

Boundless Bio IPO

Boundless Bio is set to debut on the Nasdaq stock market this week, focusing on oncogene-amplified cancers, backed by Bayer.

Offer Details

• Boundless Bio will issue around 6.3 million shares at an offer price of $15 to $17 per share.
• The company plans to raise up to $101 million in its IPO.

Use of Proceeds

1. The proceeds will fund research and development of ecDNA diagnostic tests and platforms.
2. Remaining funds will support working capital and general purposes.

Bold will trade under the ticker symbol BOLD on the Nasdaq exchange.

Market Trends

Biotech IPO market has seen a significant rise this year with an increase in total funds raised.

Clinical Trials

• BBI-355 is in Phase 1/2 clinical trial for oncogene-amplified cancers.
• BBI-098 is a potential CHK1 inhibitor with promising preclinical data.